Your current FreeStyle Libre reader will not work with the new FreeStyle Libre 2 sensor.

Use the FreeStyle LibreLink app available on the Apple App Store or Google Play Store to scan your FreeStyle Libre 2 sensor.

The FreeStyle Libre 2 readers will be available in South Africa towards the end of 2024.

Discovery Health Medical Scheme members should continue claiming FreeStyle Libre 2 sensors via CDE, M-KEM, Pharmacy Direct, and Medipost to avoid co-payments (depending on plan type).

If you claim from a pharmacy not listed above, the price of each sensor may be greater than the approved CGM benefit amount, and the amount billed by pharmacy would be for your own account.

PayPal icon
visa icon
mastercard icon

30 day 100% money back guarantee on your first Starter Kit (Terms and conditions apply)

money-refund

GB Mainland: 3 day delivery
Northern Ireland: 3-4 day delivery
(Estimated standard delivery)

delivery

All payments are secure and encrypted

safe

Your cart is empty

Real-World Evidence

The FreeStyle Libre 2 system is proven to result in better clinical outcomes for people with diabetes:

  • Reduces hypoglycaemia1,2
  • Decreases HbA1c3,4
  • Increases Time in Range in people with T1D3
  • Improves quality of life3,5
Women with coffee smiling while the FreeStyle Libre sensor is visibile on the back of her arm.
Women with coffee smiling while the FreeStyle Libre sensor is visibile on the back of her arm.
Women with coffee smiling while the FreeStyle Libre sensor is visibile on the back of her arm.

The FreeStyle Libre systems* significantly reduce hypoglycaemia in people with both Type 11 and Type22 diabetes

The FreeStyle Libre systems* significantly decrease HbA1c for people with Type 1 diabetes3

An independent study published in the New England Journal of Medicine3 shows that the FreeStyle Libre 2 system reduce HbA1c by 0.5% compared to self-monitored blood glucose at 6 months of use.

Reduced HbA1c chart

The FreeStyle Libre systems** increase %TIR for people with Type 1 diabetes

FreeStyle Libre 2 users spent 2.2 hours more in range per day3

An independent study published in the New England Journal of Medicine shows that FreeStyle Libre 2 users increased their Time in Range by over 2 hours per day:3

  • 156 people with T1D ≥16 years with HbA1c ≥7.5% participated in a randomised, controlled study

  • FreeStyle Libre 2 users spent 2.2 hours more time in range per day at 6 months of use vs those using self-monitored blood glucose
Increased time chart

Making glucose monitoring easy for everyone3

Discover how the FreeStyle Libre 2 System and apps can help manage glucose levels with ease and confidence4 for people aged 4 and older.

FreeStyle Libre 3 IOS Generic Phone mmol w/ comma
References & Disclaimers 
 

* FreeStyle Libre systems refers to the FreeStyle Libre 2 systems. The data from these studies was collected using the FreeStyle Libre system and the FreeStyle Libre 2 system.

◊ The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check the website for more information about device compatibility before using the app. Use of FreeStyle LibreLink may require registration with LibreView.

§ The LibreLinkUp app is only compatible with certain mobile device and operating systems. Please check www.librelinkup.com for more information about device compatibility before using the app. Use of LibreLinkUp requires registration with LibreView. The LibreLinkUp mobile app is not intended to be a primary glucose monitor: home users must consult their primary device(s) and consult a healthcare professional before making any medical interpretation and therapy adjustments from the information provided by the app.

₼ The LibreView website is only compatible with certain operating systems and browsers. Please check www.libreview.com for additional information.

1. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254-2263.

2. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1): 55-73.

3. Leelarathna, L. N Engl J Med. (2022): DOI: 10.1056/NEJMoa2205650.

4. Yaron, M. Diabetes Care (2019): https://doi.org/10.2337/dc18-0166

5. Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diab Res Care. 2019. https://doi:10.1136/bmjdrc-2019-000809.